Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Auditor change
Benitec Biopharma Inc. (BNTC) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/11/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and between Benitec Biopharma Inc. and Citizens JMP Securities, LLC",
"Form of Pre-Funded Warrant",
"Form of Common Warrant",
"Warrant Agency Agreement, by and between Benitec Biopharma Inc. and Computershare Trust Company, N.A",
"Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering HAYWARD, Calif., Aug. 08, 2023 — Benitec Biopharma Inc. , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock. Each share of common stock is being sold together with one common warrant to purchase one share of common stock at a combined offering price of $1.93 and each pre-funded warrant, if any, is being sold together with one common warrant to purchase one share of common stock at a combined off...",
"Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering HAYWARD, Calif., August 11, 2023 — Benitec Biopharma Inc. , a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock. Each share of common stock was sold together with one common warrant to purchase one share of common stock at a combined offering price of $1.93 and each pre-funded warrant was sold together with one common warrant to purchase one share of common stock at a combined offe..."
08/10/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
07/25/2023 8-K Quarterly results
05/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update"
03/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
02/13/2023 8-K Quarterly results
01/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program"
11/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update"
10/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/16/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between Benitec Biopharma Inc. and JMP Securities LLC",
"Form of Pre-Funded Warrant",
"Form of Common Warrant",
"Warrant Agency Agreement, by and between Benitec Biopharma Inc. and Computershare Trust Company, N.A",
"Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering HAYWARD, Calif., September 12, 2022 - Benitec Biopharma Inc. , a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock is being sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 ...",
"Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering HAYWARD, Calif., Sept. 16, 2022 — Benitec Biopharma Inc. , a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of..."
09/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/02/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update"
05/16/2022 8-K Quarterly results
02/14/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Benitec Biopharma Discloses Q2 2022 Financial Results"
12/21/2021 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc., effective December 17, 2021",
"Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc., effective December 17, 2021"
12/13/2021 8-K Quarterly results
11/15/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Benitec Biopharma Discloses Q1 2022 Financial Results"
09/20/2021 8-K Quarterly results
09/20/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
02/24/2021 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 24, 2021 BENITEC BIOPHARMA INC. Delaware 001-39267 84-462-0206 3940 Trust Way, Hayward, California 94545 Registrant's Telephone Number, Including Area Code: 780-0819 : Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Presentation of Benitec Biopharma Inc.",
"Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study Highlights from the Interim Analysis:"
12/15/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity Incentive and Compensation Plan (Executives)",
"Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity Incentive and Compensation Plan (Executives)",
"Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity Incentive and Compensation Plan (Non-Employee Directors)"
12/14/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan",
"Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan"
11/03/2020 8-K Auditor change
Docs: "Letter from Squar Milner LLP"
10/27/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/06/2020 8-K Quarterly results
09/23/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : September 23, 2020 BENITEC BIOPHARMA INC. Delaware 001-39267 84-462-0206 3940 Trust Way, Hayward, California 94545 Registrant's Telephone Number, Including Area Code: 780-0819 : Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results"
08/17/2020 8-K Quarterly results
06/05/2020 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from Grant Thornton Audit Pty Ltd",
"Letter from Grant Thornton Audit Pty Ltd"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy